<DOC>
	<DOCNO>NCT01035671</DOCNO>
	<brief_summary>This Phase 2a double-blind , placebo-controlled study two dose level A0001 give twice daily 28 day . Potential subject screen first determine eligibility , randomize receive either high dose A0001 , low dose A0001 placebo 28 day . Eligible subject return within 21 day screen baseline visit randomization one three potential treatment . The subject require take 3 capsule study medication morning morning meal 3 capsule study medication night even meal 28 day . Additional visit clinic plan Day 14 Day 28 , time number clinical biochemical assessment do .</brief_summary>
	<brief_title>Safety Efficacy Study A0001 Subjects With Friedreich 's Ataxia</brief_title>
	<detailed_description />
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Tocopherylquinone</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<criteria>Individuals genetically confirm Friedreich 's Ataxia ( GAA point mutation ) Impaired Glucose Tolerance , measure Oral GTT Overt Diabetes Mellitus Presence clinically significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>